Overview
Roche Diagnostics Polska focuses on drug discovery, diagnostics and digital health solutions. The company develops medicines, therapies and diagnostic solutions, conducts clinical trials, and acts as the responsible entity or its representative for medicinal products authorised for marketing.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
News
Press Conference on Hemophilia A on August 31, 2026
Information on the Reimbursement Status of Hemlibra (emicizumab)
Information on the Reimbursement Status of Hemlibra (emicizumab)
Information on the Reimbursement Status of Hemlibra (emicizumab)
Important Information Regarding the End of Distribution of Gavreto (pralsetinib) by Roche Polska
Information on the Reimbursement Status of Hemlibra (emicizumab) - Update April 2, 2026
Industry
Bank accounts
Registered as a VAT taxpayer on 2004-11-01. Active
24 1880 0009 0000 0011 0283 4001- 51 1880 0009 0000 0011 0283 4000
- 90 1880 0009 0000 0011 0253 9000
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jul 2, 2014 | Call to creditors |
Public aid
No public aid cases recorded in the last 10 years.
European Funds
2 projects recorded: 1 from FE lists ($2,030,913) and 1 Commission grant (FTS) ($1,828,915).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2021-03-19 | Procurement of rapid antigene tests for diagnostic of covid-19 | $1.8M$1,828,915 | 2.2.26 - Instrument for emergency support within the Union (ESI) | |
| 2020-04-01 | Sztuczna inteligencja wspierająca podejmowanie decyzji medycznych w procesie leczenia pacjenta z cukrzycą i leczenia powikłań z nią związanych | $2.0M$2,030,913 | Program Operacyjny Inteligentny Rozwój |
Tenders
814 tenders recorded as contractor: 454 national ($44,953,715) and 360 EU ($1,127,308,238).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Oct 12, 2026 | Dostawa implantów do zabiegów ortopedycznych, implantów do zabiegów chirurgicznych i materiałów jednorazowych dla SP ZOZ MSWiA w Szczecinie | –– | Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych i Administracji w Szczecinie | |
| Oct 9, 2026 | Sukcesywne dostawy odczynników laboratoryjnych dla poszczególnych Klinik i Zakładów umb, do celów naukowo-badawczych, z podziałem na 3 części | –– | Uniwersytet Medyczny w Białymstoku | |
| Oct 9, 2026 | Dostawę odczynników, kalibratorów, systemu kontroli i materiałów zużywalnych oraz dzierżawę analizatorów dla sp zoz w garwolinie w okresie 36 miesięcy | –– | Samodzielny Publiczny Zakład Opieki Zdrowotnej w Garwolinie |
Public sector contracts
Roche Diagnostics Polska is the contractor in 255 public sector contracts, worth PLN 154.48m in total. They were signed with 117 public buyers. The largest number (2) were signed with Zachodniopomorskie Centrum Onkologii.
| Public buyer | Value | |
|---|---|---|
| Samodzielny Publiczny Zakład Opieki Zdrowotnej Stacja Pogotowia Ratunkowego w Gdańsku | PLN 21,855 | |
| Wojewódzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im.M.Kopernika w Łodzi | PLN 437.00 | |
| Specjalistyczny Szpital Im. Dra Alfreda Sokołowskiego | PLN 360.00 | |
| Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego | PLN 17,912 | |
| Wojewódzki Szpital Podkarpacki Im. Jana Pawła II w Krośnie | PLN 291.70 |
Public procurement disputes (KIO)
Roche Diagnostics Polska has been a party to 155 cases before the National Appeal Chamber (since 2008). It filed 97 appeals (39 upheld, 27 dismissed, 27 discontinued, 1 rejected). In 58 cases it joined the proceedings as a participant.
Authorized Representatives
Manner of representation
Two members of the management board acting jointly, a member of the management board jointly with a commercial proxy, two commercial proxies acting jointly.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Roche Finance Ltd. | 1,313 | $3,546,731.50 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Komtur Polskasp. z o.o. | $424,362,396.43 | komtur.pl | ||
| Sanofisp. z o.o. | $384,123,246.36 | sanofi.com | ||
| MSD Polska Dystrybucjasp. z o.o. | $341,786,056.16 | msd.pl | ||
| Pfizer Trading Polskasp. z o.o. | $299,067,553.99 | pfizer.pl | ||
| Bristol-Myers Squibb Polskasp. z o.o. | $230,722,737.87 | bms.com | ||
| Servier Polska Servicessp. z o.o. | $157,143,144.15 | servier.pl | ||
| Phoenix Pharma Polskasp. z o.o. | $140,768,509.34 | phoenixpharma.pl | ||
| Medezinsp. z o.o. | $107,559,392.19 | medezin.pl | ||
| Olympus Polskasp. z o.o. | $104,605,078.34 | olympus.pl | ||
| Magnapharm Polandsp. z o.o. | $90,512,785.67 | magnapharm.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-10-01 | Share capital change (8,000,000.00 PLN → 13,130,000.00 PLN) | |
| 2025-10-01 | PKD change (Removed: 46.69.Z, 72.11.Z, 85.59.B, 95.11.Z; Added: 46.64.Z, 72.10.Z, 85.59.D, 95.10.Z) | |
| 2024-02-05 | Address change (Ul. Bobrowiecka 8, 00-728, Warszawa → Ul. Domaniewska 28, 02-672, Warszawa) | |
| 2019-01-18 | Address change (Wybrzeże Gdyńskie 6b, 01-531, Warszawa → Ul. Bobrowiecka 8, 00-728, Warszawa) | |
| 2015-07-17 | PKD change (Removed: 32.50.Z, 33.19.Z, 33.20.Z, 43.2, 43.3, 43.99.Z, 45.11.Z, 46.51.Z, 46.52.Z, 46.66.Z, 58.12.Z, 58.14.Z, 58.19.Z, 62.02.Z, 62.03.Z, 62.09.Z, 63.99.Z, 68.20.Z, 72.19.Z, 77.39.Z, 85.60.Z) |
FAQ
Last updated: 2026-10-07